	US 12,403,130 B2
	Pharmaceutical combinations for treating cancer
Thomas Jorg Mehrling, Hunenberg (CH); and Enrique Maria Ocio, Salamanca (ES)
Assigned to Purdue Pharmaceutical Products L.P., Stamford, CT (US)
Filed by Purdue Pharmaceutical Products L.P., Stamford, CT (US)
Filed on Jun. 14, 2024, as Appl. No. 18/743,233.
Application 18/743,233 is a continuation of application No. 18/086,958, filed on Dec. 22, 2022, granted, now 12,048,688.
Application 18/086,958 is a continuation of application No. 17/212,765, filed on Mar. 25, 2021, granted, now 11,559,516, issued on Jan. 24, 2023.
Application 17/212,765 is a continuation of application No. 16/517,936, filed on Jul. 22, 2019, abandoned.
Application 16/517,936 is a continuation of application No. 15/985,097, filed on May 21, 2018, granted, now 10,406,138, issued on Sep. 10, 2019.
Application 15/985,097 is a continuation of application No. 15/314,162, abandoned, previously published as PCT/EP2015/061571, filed on May 26, 2015.
Claims priority of application No. 1409471 (GB), filed on May 28, 2014.
Prior Publication US 2025/0009715 A1, Jan. 9, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4184 (2006.01); A61K 31/407 (2006.01); A61K 31/427 (2006.01); A61K 31/502 (2006.01); A61K 31/5377 (2006.01); A61K 31/55 (2006.01); A61K 31/573 (2006.01); A61K 31/58 (2006.01); A61K 31/69 (2006.01); A61K 38/05 (2006.01); A61K 38/06 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/4184 (2013.01) [A61K 31/407 (2013.01); A61K 31/427 (2013.01); A61K 31/502 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61K 31/69 (2013.01); A61K 38/05 (2013.01); A61K 38/06 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01)]

9 Claims

1. A method of treating glioblastoma in a patient in need thereof comprising administering to said patient an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof:

wherein the patient is also being treated with radiotherapy.